Mereo BioPharma Group plc

Share Issue/Capital Change • Feb 20, 2020

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 6604D

Mereo BioPharma Group plc

20 February 2020

Mereo BioPharma Group plc

("Mereo" or the "Company")

Notification of Director and other PDMR Dealings

London, February 20, 2020 - Mereo BioPharma Group plc (AIM: MPH, NASDAQ: MREO), a clinical stage UK based biopharmaceutical company focused on rare diseases, on February 20, 2020 granted incentive awards as set out below to persons discharging managerial responsibilities (PDMRs). All the awards were granted for nil consideration and shall ordinarily be forfeit (to the extent unvested) upon cessation of service.

Options to acquire American Depositary Shares ("ADSs") at an exercise price of $1.84 per ADS (Fair Market Value at grant) under the Mereo BioPharma Group plc 2019 Equity Incentive Plan (an employees' share scheme):

Name of PDMR	Position	Number of ADSs over which Option granted
Denise Scots-Knight	Chief Executive Officer	175,000
Alastair MacKinnon	Chief Medical Officer	85,000
Richard Jones	Chief Financial Officer	85,000
Charles Sermon	General Counsel	85,000
John Richard	Head of Corporate Development	85,000
Wills Hughes-Wilson	Head of Patient Access and Commercial Planning	50,000

These Options shall normally vest and become exercisable as to one quarter on the first anniversary of their grant date and, thereafter, as to the balance in equal monthly instalments over the three-year period following such anniversary.

Options to acquire ADSs at an exercise price of $1.84 per ADS (Fair Market Value at grant) under the Mereo BioPharma Group plc 2019 Non-Employee Equity Incentive Plan:

Name of PDMR	Position	Number of ADSs over which Option granted
Peter Fellner	Chairman	11,000
Anders Ekblom	Director	11,000
Peter Bains	Director	11,000
Kunal Kashyap	Director	11,000
Paul Blackburn	Director	11,000
Deepa Pakianathan	Director	11,000
Michael Wyzga	Director	11,000

These Options shall normally vest and become exercisable in equal monthly instalments over the year following their grant date.

The below announcement and notification is made in accordance with the EU Market Abuse Regulation. The forms required under the EU Market Abuse Regulation follow.

1

Details of the person discharging managerial responsibilities

a)

Name

Denise Scots-Knight

2

Reason for the notification

a)

Position/status

Chief Executive Officer

b)

Initial notification/ Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Mereo BioPharma Group plc

b)

LEI

213800U8JQHIJOS5AS09

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

AMERICAN DEPOSITARY SHARE (ADS), EACH REPRESENTING 5 MEREO BIOPHARMA GROUP PLC ORDINARY SHARES OF GBP0.003 EACH

b)

Nature of the transaction

GRANT OF AN OPTION (FOR NO CONSIDERATION) UNDER THE MEREO BIOPHARMA GROUP PLC 2019 EQUITY INCENTIVE PLAN. THE EXERCISE PRICE IS US$1.84 PER ADS (FAIR MARKET VALUE AT GRANT)

c)

Price(s) and volume(s)

Price(s)	Volume(s)
NIL	175,000

d)

Aggregated information:  volume, Price

NOT APPLICABLE - SINGLE TRANSACTION

e)

Date of the transaction

February 20, 2020

f)

Place of the transaction

Outside of a trading venue

1

Details of the person discharging managerial responsibilities

a)

Name

Alastair MacKinnon

2

Reason for the notification

a)

Position/status

Chief Medical Officer

b)

Initial notification/ Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Mereo BioPharma Group plc

b)

LEI

213800U8JQHIJOS5AS09

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

AMERICAN DEPOSITARY SHARE (ADS), EACH REPRESENTING 5 MEREO BIOPHARMA GROUP PLC ORDINARY SHARES OF GBP0.003 EACH

b)

Nature of the transaction

GRANT OF AN OPTION (FOR NO CONSIDERATION) UNDER THE MEREO BIOPHARMA GROUP PLC 2019 EQUITY INCENTIVE PLAN. THE EXERCISE PRICE IS US$1.84 PER ADS (FAIR MARKET VALUE AT GRANT)

c)

Price(s) and volume(s)

Price(s)	Volume(s)
NIL	85,000

d)

Aggregated information:  volume, Price

NOT APPLICABLE - SINGLE TRANSACTION

e)

Date of the transaction

February 20, 2020

f)

Place of the transaction

Outside of a trading venue

1

Details of the person discharging managerial responsibilities

a)

Name

Richard Jones

2

Reason for the notification

a)

Position/status

Chief Financial Officer

b)

Initial notification/ Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Mereo BioPharma Group plc

b)

LEI

213800U8JQHIJOS5AS09

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

AMERICAN DEPOSITARY SHARE (ADS), EACH REPRESENTING 5 MEREO BIOPHARMA GROUP PLC ORDINARY SHARES OF GBP0.003 EACH

b)

Nature of the transaction

GRANT OF AN OPTION (FOR NO CONSIDERATION) UNDER THE MEREO BIOPHARMA GROUP PLC 2019 EQUITY INCENTIVE PLAN. THE EXERCISE PRICE IS US$1.84 PER ADS (FAIR MARKET VALUE AT GRANT)

c)

Price(s) and volume(s)

Price(s)	Volume(s)
NIL	85,000

d)

Aggregated information:  volume, Price

NOT APPLICABLE - SINGLE TRANSACTION

e)

Date of the transaction

February 20, 2020

f)

Place of the transaction

Outside of a trading venue

1

Details of the person discharging managerial responsibilities

a)

Name

Charles Sermon

2

Reason for the notification

a)

Position/status

General Counsel

b)

Initial notification/ Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Mereo BioPharma Group plc

b)

LEI

213800U8JQHIJOS5AS09

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

AMERICAN DEPOSITARY SHARE (ADS), EACH REPRESENTING 5 MEREO BIOPHARMA GROUP PLC ORDINARY SHARES OF GBP0.003 EACH

b)

Nature of the transaction

GRANT OF AN OPTION (FOR NO CONSIDERATION) UNDER THE MEREO BIOPHARMA GROUP PLC 2019 EQUITY INCENTIVE PLAN. THE EXERCISE PRICE IS US$1.84 PER ADS (FAIR MARKET VALUE AT GRANT)

c)

Price(s) and volume(s)

Price(s)	Volume(s)
NIL	85,000

d)

Aggregated information:  volume, Price

NOT APPLICABLE - SINGLE TRANSACTION

e)

Date of the transaction

February 20, 2020

f)

Place of the transaction

Outside of a trading venue

1

Details of the person discharging managerial responsibilities

a)

Name

Wills Hughes-Wilson

2

Reason for the notification

a)

Position/status

Head of Patient Access and Commercial Planning

b)

Initial notification/ Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Mereo BioPharma Group plc

b)

LEI

213800U8JQHIJOS5AS09

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

AMERICAN DEPOSITARY SHARE (ADS), EACH REPRESENTING 5 MEREO BIOPHARMA GROUP PLC ORDINARY SHARES OF GBP0.003 EACH

b)

Nature of the transaction

GRANT OF AN OPTION (FOR NO CONSIDERATION) UNDER THE MEREO BIOPHARMA GROUP PLC 2019 EQUITY INCENTIVE PLAN. THE EXERCISE PRICE IS US$1.84 PER ADS (FAIR MARKET VALUE AT GRANT)

c)

Price(s) and volume(s)

Price(s)	Volume(s)
NIL	50,000

d)

Aggregated information:  volume, Price

NOT APPLICABLE - SINGLE TRANSACTION

e)

Date of the transaction

February 20, 2020

f)

Place of the transaction

Outside of a trading venue

1

Details of the person discharging managerial responsibilities

a)

Name

John Richard

2

Reason for the notification

a)

Position/status

Head of Corporate Development

b)

Initial notification/ Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Mereo BioPharma Group plc

b)

LEI

213800U8JQHIJOS5AS09

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

AMERICAN DEPOSITARY SHARE (ADS), EACH REPRESENTING 5 MEREO BIOPHARMA GROUP PLC ORDINARY SHARES OF GBP0.003 EACH

b)

Nature of the transaction

GRANT OF AN OPTION (FOR NO CONSIDERATION) UNDER THE MEREO BIOPHARMA GROUP PLC 2019 EQUITY INCENTIVE PLAN. THE EXERCISE PRICE IS US$1.84 PER ADS (FAIR MARKET VALUE AT GRANT)

c)

Price(s) and volume(s)

Price(s)	Volume(s)
NIL	85,000

d)

Aggregated information: volume, Price

NOT APPLICABLE - SINGLE TRANSACTION

e)

Date of the transaction

February 20, 2020

f)

Place of the transaction

Outside of a trading venue

1

Details of the person discharging managerial responsibilities

a)

Name

Peter Fellner

2

Reason for the notification

a)

Position/status

Chairman

b)

Initial notification/ Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Mereo BioPharma Group plc

b)

LEI

213800U8JQHIJOS5AS09

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

AMERICAN DEPOSITARY SHARE (ADS), EACH REPRESENTING 5 MEREO BIOPHARMA GROUP PLC ORDINARY SHARES OF GBP0.003 EACH

b)

Nature of the transaction

GRANT OF AN OPTION (FOR NO CONSIDERATION) UNDER THE MEREO BIOPHARMA GROUP PLC 2019 NON-EMPLOYEE EQUITY INCENTIVE PLAN. THE EXERCISE PRICE IS US$1.84 PER ADS (FAIR MARKET VALUE AT GRANT).

c)

Price(s) and volume(s)

Price(s)	Volume(s)
NIL	11,000

d)

Aggregated information:  volume, Price

NOT APPLICABLE - SINGLE TRANSACTION

e)

Date of the transaction

February 20, 2020

f)

Place of the transaction

Outside of a trading venue

1

Details of the person discharging managerial responsibilities

a)

Name

Anders Ekblom

2

Reason for the notification

a)

Position/status

Director

b)

Initial notification/ Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Mereo BioPharma Group plc

b)

LEI

213800U8JQHIJOS5AS09

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

AMERICAN DEPOSITARY SHARE (ADS), EACH REPRESENTING 5 MEREO BIOPHARMA GROUP PLC ORDINARY SHARES OF GBP0.003 EACH

b)

Nature of the transaction

GRANT OF AN OPTION (FOR NO CONSIDERATION) UNDER THE MEREO BIOPHARMA GROUP PLC 2019 NON-EMPLOYEE EQUITY INCENTIVE PLAN. THE EXERCISE PRICE IS US$1.84 PER ADS (FAIR MARKET VALUE AT GRANT).

c)

Price(s) and volume(s)

Price(s)	Volume(s)
NIL	11,000

d)

Aggregated information:  volume, Price

NOT APPLICABLE - SINGLE TRANSACTION

e)

Date of the transaction

February 20, 2020

f)

Place of the transaction

Outside of a trading venue

1

Details of the person discharging managerial responsibilities

a)

Name

Peter Bains

2

Reason for the notification

a)

Position/status

Director

b)

Initial notification/ Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Mereo BioPharma Group plc

b)

LEI

213800U8JQHIJOS5AS09

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

AMERICAN DEPOSITARY SHARE (ADS), EACH REPRESENTING 5 MEREO BIOPHARMA GROUP PLC ORDINARY SHARES OF GBP0.003 EACH

b)

Nature of the transaction

GRANT OF AN OPTION (FOR NO CONSIDERATION) UNDER THE MEREO BIOPHARMA GROUP PLC 2019 NON-EMPLOYEE EQUITY INCENTIVE PLAN. THE EXERCISE PRICE IS US$1.84 PER ADS (FAIR MARKET VALUE AT GRANT).

c)

Price(s) and volume(s)

Price(s)	Volume(s)
NIL	11,000

d)

Aggregated information:  volume, Price

NOT APPLICABLE - SINGLE TRANSACTION

e)

Date of the transaction

February 20, 2020

f)

Place of the transaction

Outside of a trading venue

1

Details of the person discharging managerial responsibilities

a)

Name

Kunal Kashyap

2

Reason for the notification

a)

Position/status

Director

b)

Initial notification/ Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Mereo BioPharma Group plc

b)

LEI

213800U8JQHIJOS5AS09

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

AMERICAN DEPOSITARY SHARE (ADS), EACH REPRESENTING 5 MEREO BIOPHARMA GROUP PLC ORDINARY SHARES OF GBP0.003 EACH

b)

Nature of the transaction

GRANT OF AN OPTION (FOR NO CONSIDERATION) UNDER THE MEREO BIOPHARMA GROUP PLC 2019 NON-EMPLOYEE EQUITY INCENTIVE PLAN. THE EXERCISE PRICE IS US$1.84 PER ADS (FAIR MARKET VALUE AT GRANT).

c)

Price(s) and volume(s)

Price(s)	Volume(s)
NIL	11,000

d)

Aggregated information:  volume, Price

NOT APPLICABLE - SINGLE TRANSACTION

e)

Date of the transaction

February 20, 2020

f)

Place of the transaction

Outside of a trading venue

1

Details of the person discharging managerial responsibilities

a)

Name

Paul Blackburn

2

Reason for the notification

a)

Position/status

Director

b)

Initial notification/ Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Mereo BioPharma Group plc

b)

LEI

213800U8JQHIJOS5AS09

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

AMERICAN DEPOSITARY SHARE (ADS), EACH REPRESENTING 5 MEREO BIOPHARMA GROUP PLC ORDINARY SHARES OF GBP0.003 EACH

b)

Nature of the transaction

GRANT OF AN OPTION (FOR NO CONSIDERATION) UNDER THE MEREO BIOPHARMA GROUP PLC 2019 NON-EMPLOYEE EQUITY INCENTIVE PLAN. THE EXERCISE PRICE IS US$1.84 PER ADS (FAIR MARKET VALUE AT GRANT).

c)

Price(s) and volume(s)

Price(s)	Volume(s)
NIL	11,000

d)

Aggregated information:  volume, Price

NOT APPLICABLE - SINGLE TRANSACTION

e)

Date of the transaction

February 20, 2020

f)

Place of the transaction

Outside of a trading venue

1

Details of the person discharging managerial responsibilities

a)

Name

Deepa Pakianathan

2

Reason for the notification

a)

Position/status

Director

b)

Initial notification/ Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Mereo BioPharma Group plc

b)

LEI

213800U8JQHIJOS5AS09

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

AMERICAN DEPOSITARY SHARE (ADS), EACH REPRESENTING 5 MEREO BIOPHARMA GROUP PLC ORDINARY SHARES OF GBP0.003 EACH

b)

Nature of the transaction

GRANT OF AN OPTION (FOR NO CONSIDERATION) UNDER THE MEREO BIOPHARMA GROUP PLC 2019 NON-EMPLOYEE EQUITY INCENTIVE PLAN. THE EXERCISE PRICE IS US$1.84 PER ADS (FAIR MARKET VALUE AT GRANT).

c)

Price(s) and volume(s)

Price(s)	Volume(s)
NIL	11,000

d)

Aggregated information:  volume, Price

NOT APPLICABLE - SINGLE TRANSACTION

e)

Date of the transaction

February 20, 2020

f)

Place of the transaction

Outside of a trading venue

1

Details of the person discharging managerial responsibilities

a)

Name

Michael Wyzga

2

Reason for the notification

a)

Position/status

Director

b)

Initial notification/ Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Mereo BioPharma Group plc

b)

LEI

213800U8JQHIJOS5AS09

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

AMERICAN DEPOSITARY SHARE (ADS), EACH REPRESENTING 5 MEREO BIOPHARMA GROUP PLC ORDINARY SHARES OF GBP0.003 EACH

b)

Nature of the transaction

GRANT OF AN OPTION (FOR NO CONSIDERATION) UNDER THE MEREO BIOPHARMA GROUP PLC 2019 NON-EMPLOYEE EQUITY INCENTIVE PLAN. THE EXERCISE PRICE IS US$1.84 PER ADS (FAIR MARKET VALUE AT GRANT).

c)

Price(s) and volume(s)

Price(s)	Volume(s)
NIL	11,000

d)

Aggregated information:  volume, Price

NOT APPLICABLE - SINGLE TRANSACTION

e)

Date of the transaction

February 20, 2020

f)

Place of the transaction

Outside of a trading venue

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

DSHURRNRRSUUUAR